| Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia CC Smith, Q Wang, CS Chin, S Salerno, LE Damon, MJ Levis, AE Perl, ... Nature 485 (7397), 260-263, 2012 | 841 | 2012 |
| Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD CC Smith, EA Lasater, X Zhu, KC Lin, WK Stewart, LE Damon, S Salerno, ... Blood, The Journal of the American Society of Hematology 121 (16), 3165-3171, 2013 | 157 | 2013 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry LM Wodicka, P Ciceri, MI Davis, JP Hunt, M Floyd, S Salerno, XH Hua, ... Chemistry & biology 17 (11), 1241-1249, 2010 | 132 | 2010 |
| Clinical pharmacology studies in critically ill children N Thakkar, S Salerno, CP Hornik, D Gonzalez Pharmaceutical research 34, 7-24, 2017 | 58 | 2017 |
| Association between nephrotoxic drug combinations and acute kidney injury in the neonatal intensive care unit SN Salerno, Y Liao, W Jackson, RG Greenberg, CJ McKinzie, ... The Journal of pediatrics 228, 213-219, 2021 | 41 | 2021 |
| Pediatric drug-drug interaction studies: barriers and opportunities SN Salerno, GJ Burckart, SM Huang, D Gonzalez Clinical pharmacology and therapeutics 105 (5), 1067, 2019 | 37 | 2019 |
| Physiologically‐based pharmacokinetic modeling characterizes the CYP3A‐mediated drug‐drug interaction between fluconazole and sildenafil in infants SN Salerno, A Edginton, JG Gerhart, MM Laughon, N Ambalavanan, ... Clinical Pharmacology & Therapeutics 109 (1), 253-262, 2021 | 28 | 2021 |
| Physiologically‐based pharmacokinetic modeling of fluconazole using plasma and cerebrospinal fluid samples from preterm and term infants JG Gerhart, KM Watt, A Edginton, KC Wade, SN Salerno, DK Benjamin Jr, ... CPT: Pharmacometrics & Systems Pharmacology 8 (7), 500-510, 2019 | 15 | 2019 |
| Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin–Tazobactam Safety in Infants S Salerno, CP Hornik, M Cohen-Wolkowiez, PB Smith, LC Ku, MS Kelly, ... The Pediatric infectious disease journal 36 (9), 855-859, 2017 | 14 | 2017 |
| Development of an adult physiologically based pharmacokinetic model of solithromycin in plasma and epithelial lining fluid SN Salerno, A Edginton, M Cohen‐Wolkowiez, CP Hornik, KM Watt, ... CPT: Pharmacometrics & Systems Pharmacology 6 (12), 814-822, 2017 | 13 | 2017 |
| Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia SN Salerno, J Bernhardt, M Laughon, R Jhaveri, M Massaro, D Gonzalez Journal of the Pediatric Infectious Diseases Society 7 (4), 342-345, 2018 | 9 | 2018 |
| Constitutively activating mutations at the FLT3 activation loop residue D835 are associated with clinical resistance to AC220 CC Smith, J Chin, E Lasater, AL Paguirigan, K Lin, W Stewart, S Salerno, ... Blood 120 (21), 674, 2012 | 7 | 2012 |
| Validation of FLT3-ITD as a therapeutic target in human acute myeloid leukemia CC Smith, J Chin, Q Wang, S Salerno, LE Damon, JP Hunt, MJ Levis, ... Blood 118 (21), 937, 2011 | 6 | 2011 |
| Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Use of population pharmacokinetics and electronic health records to assess piperacillin … S Salerno, CP Hornik, M Cohen-Wolkowiez, PB Smith, LC Ku, MS Kelly, ... Pediatr Infect Dis J 36 (9), 855-859, 2017 | 5 | 2017 |
| Activity of allosteric, switch-pocket, ABL/FLT3 kinase inhibitor DCC2036 against cultured and primary aml progenitors with FLT-ITD or FLT3 kinase domain mutations W Fiskus, CC Smith, J Smith, SC Wise, E Lasater, LE Damon, S Salerno, ... Blood 118 (21), 2611, 2011 | 5 | 2011 |
| Leveraging physiologically based pharmacokinetic modeling and experimental data to guide dosing modification of CYP3A-mediated drug-drug interactions in the pediatric population SN Salerno, FO Carreño, AN Edginton, M Cohen-Wolkowiez, D Gonzalez Drug Metabolism and Disposition 49 (9), 844-855, 2021 | 4 | 2021 |
| Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients SN Salerno, EV Capparelli, H McIlleron, JG Gerhart, JB Dumond, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (7 …, 2023 | 3 | 2023 |
| Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency SN Salerno, R Deng, T Kakkar CPT: Pharmacometrics & Systems Pharmacology 11 (10), 1316-1327, 2022 | 3 | 2022 |
| Single molecule real time (SMRT™) sequencing sensitively detects polyclonal and compound BCR-ABL in patients who relapse on kinase inhibitor therapy CC Smith, M Brown, J Chin, C Kasap, S Salerno, LE Damon, K Travers, ... Blood 118 (21), 3752, 2011 | 3 | 2011 |
| Analysis of in vitro activity of the clinically-active ABL/FLT3 inhibitor Ponatinib (AP24534) against AC220-resistant FLT3-ITD mutants CC Smith, LE Damon, X Zhu, S Salerno, N Shah Blood 118 (21), 930, 2011 | 2 | 2011 |
